Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417461 | 0.87 | ALDH1A1 (0.47) | TSHRSMN1; SMN2MAPK1TDP1L3MBTL1 | |
| SCHEMBL30811273 | 0.87 | ALDH1A1 (0.47) | TSHRSMN1; SMN2MAPK1TDP1L3MBTL1 | |
| SCHEMBL5425298 | 0.86 | CYP4F2 (0.40) | KDRGPBAR1CYSLTR1CYP4F2CYP4A11 | |
| SCHEMBL5432902 | 0.85 | BCHE (0.38) | FYNTSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL6041467 | 0.85 | ALDH1A1 (0.34) | TSHRSMN1; SMN2CYP4F2CYP4A11MAPK1 | |
| SCHEMBL6043425 | 0.84 | CYP11B1 (0.38) | KDRGPBAR1CYSLTR1FYNMAPK1 | |
| SCHEMBL5281505 | 0.83 | HRH3 (0.40) | CYSLTR1FYNSMN1; SMN2NR1H4MAPK1 | |
| SCHEMBL6088577 | 0.82 | FYN (0.47) | KDRGPBAR1CYSLTR1FYNTSHR | |
| SCHEMBL6041748 | 0.82 | CYP11B1 (0.36) | KDRCYSLTR1FYNNR1H4MAPK1 | |
| SCHEMBL8216043 | 0.79 | KCNA3 (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | KDR 4266/4885GPBAR1 244/4885CYSLTR1 855/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | KDR 4589/4885GPBAR1 3496/4885CYSLTR1 2454/4885 |
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | KDR 1906/4885GPBAR1 38/4885CYSLTR1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.